Memorandum of Understanding
Between MAPS and Jeff Morley, Ph.D.

December 12, 2006

1. MAPS welcomes the interest of Jeff Morley, Ph.D., in becoming the Principle Investigator (PI) of a MAPS-sponsored Phase 2 pilot study into the use of MDMA-assisted psychotherapy in subjects who are or were Canadian police officers (Royal Canadian Mounted Police (RCMP) or other police forces) or members of the Canadian armed forces, with work-related posttraumatic stress disorder (PTSD).

2. Dr. Morley's study will be designed in a similar manner to the designs used in MDMA/PTSD Phase 2 studies that MAPS is sponsoring in Israel, Spain and the United States.

3. MAPS pledges to support Dr. Morley's study with up to $100,000 if necessary, once the study is fully approved, and perhaps more. Dr. Morley pledges to try to raise some funds from Canadian donors, with success not required.

4. MAPS will assist with the protocol design and approval process by making available an updated MDMA literature review and by working collaboratively with Dr. Morley to develop an English-language informed consent form and a protocol for submission to a local ethics committee and to Health Canada officials.

5. MAPS will supply MDMA, purchased in Switzerland, for the study.

6. MAPS has introduced Dr. Morley to Dr. Ingrid Pacey, M.D., a Vancouver psychiatrist with expertise in PTSD and in Dr. Stan Grof's Holotropic Breathwork, with the intention of Dr. Morley and Dr. Pacey working together as a male/female co-therapist team.

Multidisciplinary Association for Psychedelic Studies
MAPS • Rick Doblin • 3 Francis Street • Belmont, MA. 02478-2218 •
617 484-8711, Fax: -8427 • www.maps.org • rick@maps.org



7. MAPS will pay all expenses to bring Dr. Morley and Dr. Pacey to Charleston, SC, for training in conducting MDMA/PTSD sessions offered by Dr. Michael Mithoefer and Annie Mithoefer, RN.

8. MAPS will submit the protocol to the FDA for review and approval after the protocol has been approved by the local ethics committee and Health Canada. MAPS will work with Dr. Morley, the local ethics committee, Health Canada and the FDA until we have a common protocol that has been approved by all the regulatory authorities.

9. MAPS will provide Case Report Forms and clinical monitoring to facilitate acceptance of the data by Health Canada and the FDA.

10. Dr. Morley will submit the data gathered to Health Canada and also to FDA as part of MAPS' Institutional New Drug application (IND) for MDMA. As sponsor and funder of the study, MAPS technically owns the data, or if there are other funders, shares ownership of the data. Nevertheless, Dr. Morley may submit the data anywhere he chooses and may publish the data in any place or manner that he chooses. No prior approval by MAPS is required for any articles written by or interviews conducted with Dr. Morley or Dr. Pacey.

11. MAPS operates on the basis of transparency and sharing of protocols and data. MAPS will post the approved protocol and informed consent forms on the MAPS website and will share data with any researchers who request access to the data. MAPS also intends to respond to media requests about the study and considers public education to be part of its mission.

12. MAPS' long-term goals are to conduct a Phase 3 multi-site MDMA/PTSD study in the United States and Canada, and to conduct a second multi-site Phase 2 study in Israel, Switzerland and in Europe, with the intention of developing MDMA into a prescription medicine in the US, Canada and Europe.

Multidisciplinary Association for Psychedelic Studies
MAPS • Rick Doblin • 3 Francis Street • Belmont, MA. 02478-2218 •
617 484-8711, Fax: -8427 • www.maps.org • rick@maps.org



_____ _____

Rick Doblin, Ph.D
MAPS President

Jeff Morley, Ph.D.

Multidisciplinary Association for Psychedelic Studies
MAPS • Rick Doblin • 3 Francis Street • Belmont, MA. 02478-2218 •
617 484-8711, Fax: -8427 • www.maps.org • rick@maps.org